{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.9","upperLimit":"1.7","value":"0.9"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"30"}],"units":"Participants"}],"description":"The amount of time between starting treatment and attaining at least a minor response to therapy","dispersionType":"95% Confidence Interval","groups":[{"description":"This is single arm, open label, Phase II, single center study designed to evaluate the safety and efficacy of ibrutinib in previously untreated WM patients. Treatment will be administered in 4-week cycles, and participants will receive treatment for up to 48 cycles. Treatment will be comprised of ibrutinib at 420 mg per day by oral administration.\n\nIbrutinib","id":"OG000","title":"Ibrutinib"}],"paramType":"MEDIAN","populationDescription":"All participants except one determined to be ineligible","reportingStatus":"POSTED","timeFrame":"4 years","title":"Time to Response","type":"OTHER_PRE_SPECIFIED","unitOfMeasure":"months"}